Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS

Blood

Volumn 120, Issue 7, 2012, Pages 1398-1408

  Deeg, H Joachim ^a,b   Scott, Bart L ^a,b   Fang, Min ^a,b   Shulman, Howard M ^a,b   Gyurkocza, Boglarka ^a,b   Myerson, David ^a,b   Pagel, John M ^a,b   Platzbecker, Uwe ^c   Ramakrishnan, Aravind ^a,b   Radich, Jerald P ^a,b   Sandmaier, Brenda M ^a,b   Sorror, Mohamed ^a   Stirewalt, Derek L ^a,b   Wilson, Wendy A ^a   Storb, Rainer ^a,b   Appelbaum, Frederick R ^a,b   Gooley, Ted ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD45 ANTIGEN I 135; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; RADIOPHARMACEUTICAL AGENT; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TREOSULFAN; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BONE MARROW; CANCER MORTALITY; CHILD; COHORT ANALYSIS; CYTOGENETICS; FEMALE; GENETIC RISK; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SCHOOL CHILD; THROMBOCYTE COUNT; UMBILICAL CORD BLOOD; WHOLE BODY RADIATION;

EID: 84865168155     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-423046     Document Type: Article

References (46)

1. Naqvi K, Garcia-Manero G, Sardesai S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011;29(16): 2240-2246.
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood. 1998;91(3):1100]. Blood. 1997;89(6): 2079-2088. (Pubitemid 27132124)
3. Malcovati L, Germing U, Kuendgen A, et al. A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes [abstract]. Blood. 2005; 106(11):232a-233a. Abstract 788.
4. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23): 3503-3510. (Pubitemid 47315575)
5. Alessandrino EP, Della Porta MG, Bacigalupo A, et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood. 2008;112(3):895-902.
6. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100(4): 1201-1207. (Pubitemid 34864272)
7. Nevill TJ, Shepherd JD, Sutherland HJ, et al. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(2):205-213.
8. Armand P, Kim HT, DeAngelo DJ, et al. Impact of cytogenetics on outcome of de novo and therapyrelated AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007;13(6): 655-664. (Pubitemid 46767993)
9. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-829.
10. Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011;29(15):1963-1970.
11. Breems DA, van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-4797.
12. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110(13):4608-4613.
13. Petersdorf EW, Gooley T, Malkki M, Horowitz M. Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens. 2007;69(suppl 1):25-30. (Pubitemid 46625843)
14. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009; 15(12):1628-1633.
15. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. (Pubitemid 29126745)
16. Jurado M, Deeg HJ, Storer B, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant. 2002;8(3):161-169. (Pubitemid 34285075)
17. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25(27):4246-4254. (Pubitemid 47554249)
18. Armand P, Deeg HJ, Kim HT, et al. Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. Bone Marrow Transplant. 2010;45(5):877-885.
19. Haferlach C, Alpermann T, Schnittger S, et al. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood. 2012;119(9): 2122-2125.
20. Hemmati PG, Terwey TH, le Coutre PD, et al. Prognostic impact of a monosomal karyotype on the outcome of patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic stem cell transplantation [abstract]. Blood. 2011;118(21):2028
21. Brands-Nijenhuis AVM, Labopin M, Schouten HC, et al. The influence of monosomal karyotype on survival in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective survey on behalf of the acute leukemia working party of the European Group for Blood and Marrow Transplantation (EBMT) [abstract]. Blood. 2011;118(21):158.
22. Valcárcel D, Adema V, Mallo M, et al. Prognostic impact of monosomal karyotype in patients with myelodysplastic syndrome and abnormal karyotype: a report from the Spanish Group of MDS (GESMD) [abstract]. Blood. 2011;118(21):1724.
23. Yakoub-Agha I, de La Salmonière P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodsyplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients. Report of the French Society of bone marrow transplantation. J Clin Oncol. 2000;18(5): 963-971.
24. Casper J, Knauf W, Kiefer T, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood. 2004;103(2):725-731. (Pubitemid 38140111)
25. Nakai K, Kanda Y, Fukuhara S, et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia. 2005;19(3):396-401. (Pubitemid 40403316)
26. Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24): 3322-3327.
27. Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL. Pre-transplant therapy with azacitidine verus induction chemotherapy and post-transplant outcome in patients with MDS Biol Blood Marrow Transplant. doi: 2012;18(8): 1211-1218.
28. Scott BL, Storer B, Loken M, Storb R, Appelbaum FR, Deeg HJ. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant. 2005;11(1):65-73. (Pubitemid 40057995)
29. Chang CK, Storer BE, Scott BL, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood. 2007;110(4):1379-1387. (Pubitemid 47281440)
30. Litzow MR, Tarima S, Perez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010;115(9):1850-1857.
31. Sorror ML, Sandmaier BM, Storer BE, et al. Longterm outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306(17): 1874-1883.
32. Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2010;28(3):405-411.
33. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28(11):1878-1887.
34. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoieticcell transplantation. N Engl J Med. 2010;363(22): 2091-2101.
35. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [erratum appears in Biol Blood Marrow Transplant. 2010;16(2):294]. Biol Blood Marrow Transplant. 2009;15(10):1143-1238.
36. McCarthy JM, Shickle L, Roberts CH, Candler KS, Chung HM. 5Azacytidine prior to allogeneic transplantation effectively reduces relapse, TRM and overall mortality in high-risk myelodysplastic and secondary AML [abstract]. Bone Marrow Transplant. 2008;41(Suppl)212-213.
37. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89(8):3055-3060. (Pubitemid 27172594)
38. Nemecek ER, Guthrie KA, Sorror ML, et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant. 2011;17(3):341-350.
39. Pagel JM, Gooley TA, Rajendran J, et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood. 2009;114(27):5444-5453.
40. Deeg HJ, Storer BE, Boeckh M, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006;12(5):573-584. (Pubitemid 43956362)
41. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-2506.
42. Cazzola M, Della Porta MG, Travaglino E, Malcovati L. Classification and prognostic evaluation of myelodysplastic syndromes [review]. Semin Oncol. 2011;38(5):627-634.
43. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109(10):4586-4588. (Pubitemid 46743431)
44. Bejar R, LeVine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes [review]. J Clin Oncol. 2011;29(5):504-515.
45. Marcondes AM, Mhyre AJ, Stirewalt DL, Kim S-H, Dinarello CA, Deeg HJ. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci U S A. 2008;105(8):2865-2870. (Pubitemid 351723635)
46. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15): 1384-1395.